Revenue
2019
2020
Bone Biologics Corp (BBLG)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
Total cash / debt
CashTotal debt
2017
2018
2019
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1.07B | $1.07B | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $1.1M | $2.1M | $6.9M | $1.6M | $82,044 | $340,672 | $1.1M | $104,490 | $1.4M | $10.2M | $3.7M | $623,522 | — | — | — | — | — | — |
| Operating expenses | $3.2M | $4.2M | $9.4M | $3.7M | $1.1M | $825,014 | $2.4M | $2.8M | $2.6M | $20.4M | $12.0M | $3.0M | $4,806 | $5,231 | $4,520 | $3,472 | — | — |
| Operating income | −$3.2M | −$4.2M | −$9.4M | −$3.7M | −$1.1M | −$825,014 | −$2.4M | −$2.8M | −$2.6M | −$20.4M | −$12.0M | −$3.0M | — | — | — | — | — | — |
| Net income | −$3.1M | −$4.1M | −$8.9M | −$1.5M | −$1.6M | −$1.8M | −$3.4M | −$4.4M | −$7.1M | −$25.9M | −$13.9M | −$4.4M | −$5,206 | −$5,631 | −$4,920 | −$3,597 | −$10,285 | −$13,343 |
| Basic EPSper diluted share | -$2.65 | -$28.96 | -$34.01 | -$31.15 | -$0.35 | -$0.63 | -$0.47 | -$0.88 | -$1.81 | -$0.69 | -$0.49 | -$0.30 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Diluted EPSper diluted share | -$2.65 | -$28.96 | -$34.01 | -$31.15 | -$0.35 | -$0.63 | -$0.47 | -$0.88 | -$1.81 | -$0.69 | -$0.49 | -$0.30 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |